Skip to main navigation Skip to search Skip to main content

Association of Dual LRRK2 G2019S and GBA Variations with Parkinson Disease Progression

  • Roberto A. Ortega
  • , Cuiling Wang
  • , Deborah Raymond
  • , Nicole Bryant
  • , Clemens R. Scherzer
  • , Avner Thaler
  • , Roy N. Alcalay
  • , Andrew B. West
  • , Anat Mirelman
  • , Yuliya Kuras
  • , Karen S. Marder
  • , Nir Giladi
  • , Laurie J. Ozelius
  • , Susan B. Bressman
  • , Rachel Saunders-Pullman

Research output: Contribution to journalArticlepeer-review

Abstract

Importance: Despite a hypothesis that harboring a leucine-rich repeat kinase 2(LRRK2) G2019S variation and a glucocerebrosidase (GBA) variant would have a combined deleterious association with disease pathogenesis, milder clinical phenotypes have been reported in dual LRRK2 and GBA variations Parkinson disease (PD) than in GBA variation PD alone. Objective: To evaluate the association of LRRK2 G2019S and GBA variants with longitudinal cognitive and motor decline in PD. Design, Setting, and Participants: This longitudinal cohort study of continuous measures in LRRK2 PD, GBA PD, LRRK2/GBA PD, and wild-type idiopathic PD used pooled annual visit data ranging from 2004 to 2019 from the Mount Sinai Beth Israel, Parkinson Disease Biomarker Program, Harvard Biomarkers Study, Ashkenazi Jewish-LRRK2-Consortium, Parkinson Progression Marker Initiative, and SPOT-PD studies. Patients who were screened for GBA and LRRK2 variations and completed either a motor or cognitive assessment were included. Data were analyzed from May to July 2020. Main Outcomes and Measures: The associations of LRRK2 G2019S and GBA genotypes on the rate of decline in Montreal Cognitive Assessment (MoCA) and Movement Disorders Society-Unified Parkinson Disease Rating Scale-Part III scores were examined using linear mixed effects models with PD duration as the time scale. Results: Among 1193 individuals with PD (mean [SD] age, 66.6 [9.9] years; 490 [41.2%] women), 128 (10.7%) had GBA PD, 155 (13.0%) had LRRK2 PD, 21 (1.8%) had LRRK2/GBA PD, and 889 (74.5%) had idiopathic PD. Patients with GBA PD had faster decline in MoCA than those with LRRK2/GBA PD (B [SE], -0.31 [0.09] points/y; P <.001), LRRK2 PD (B [SE], -0.33 [0.09] points/y; P <.001), or idiopathic PD (B [SE], -0.23 [0.08] points/y; P =.005). There was a LRRK2 G2019S × GBA interaction in MoCA decline (B [SE], 0.22 [0.11] points/y; P =.04), but not after excluding severe GBA variations (B [SE], 0.12 [0.11] points/y; P =.28). Patients with GBA PD had significantly worse motor progression compared with those with idiopathic PD (B [SE], 0.49 [0.22] points/y; P =.03) or LRRK2 PD (B [SE], 0.77 [0.26] points/y; P =.004). Conclusions and Relevance: These findings suggest that longitudinal cognitive decline in patients with GBA PD was more severe than in those with LRRK2/GBA PD, which more closely resembled LRRK2 PD. This further supports the notion of a dominant association of LRRK2 on GBA in individuals who carry both and raises the possibility of an LRRK2 × GBA interaction. However, the biological basis of a dominant association or interaction is not clear and is apparently contrary to basic investigations. Study of a larger cohort of individuals with severe GBA variation is warranted..

Original languageEnglish (US)
Article numbere215845
JournalJAMA Network Open
Volume4
Issue number4
DOIs
StatePublished - Apr 21 2021

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Association of Dual LRRK2 G2019S and GBA Variations with Parkinson Disease Progression'. Together they form a unique fingerprint.

Cite this